지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2011.1
- 수록면
- 734 - 738 (5page)
이용수
초록· 키워드
오류제보하기
Purpose: Clopidogrel is a prodrug that requires transformation into an active metabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the P2Y12 adenosine diphosphate platelet receptor. CYP2C19 polymorphism has been reported to correlate with reduced antiplatelet activity of clopidogrel in coronary artery disease. We assessed the association between CYP2C19 polymorphism and clopidogrel resistance in patients with cerebrovascular disease. Materials and Methods: We retrospectively gathered data from patients who experienced cerebrovascular disease, received clopidogrel, and were tested for clopidogrel resistance and CYP2C19 polymorphism. Clopidogrel resistance was tested by the VerifyNow P2Y12 system, and the CYP2C19 polymorphism was tested by the Seeplex CYP2C19 ACE Genotyping system. Clopidogrel resistance was expressed in P2Y12 reaction units (PRU) and percent inhibition. High PRU and low percent inhibition suggests clopidogrel resistance. CYP2C19 polymorphisms were expressed as extensive, intermediate, and poor metabolizers. Clopidogrel resistance was assessed according to the subgroup of CYP2C19 polymorphism. Results: A total of 166 patients were evaluated. The PRU values of extensive CYP2C19 metabolizers (195.0±84.9) were significantly lower than those of intermediate and poor metabolizers (237.9±88.0, 302.2±58.9). The percent inhibition of extensive metabolizers (44.6±21.8) was significantly higher than that of intermediate and poor metabolizers (30.5±21.5, 14.0±13.4). Conclusion: Intermediate and poor metabolizing CYP2C19polymorphism is associated with reduced clopidogrel antiplatelet activity in patients with cerebrovascular disease. The clinical implications of this finding require further investigation.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Collet JP / 2009 / Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study / Lancet 73 : 309 ~ 317
Desta Z / 2002 / Clinical significance of the cytochrome P450 2C19 genetic polymorphism / Clin Pharmacokinet 41 : 913 ~ 958
Godino C / 2009 / Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying
Gremmel T / 2010 / Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition / Heart 96 : 186 ~ 189
Jaremo P / 2002 / Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel / J Intern Med 252 : 233 ~ 238
Desta Z / 2002 / Clinical significance of the cytochrome P450 2C19 genetic polymorphism / Clin Pharmacokinet 41 : 913 ~ 958
Godino C / 2009 / Comparison of VerifyNow-P2Y12 test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying
Gremmel T / 2010 / Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition / Heart 96 : 186 ~ 189
Jaremo P / 2002 / Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel / J Intern Med 252 : 233 ~ 238
이 논문의 저자 정보
최근 본 자료
댓글(0)
0